DELFI Diagnostics

DELFI Diagnostics is a cancer detection company developing blood-based tools for early screening, treatment monitoring, and drug development research. Its AI-driven platform combines whole-genome sequencing with fragmentomics, the analysis of cell-free DNA fragmentation patterns in blood, to identify signals that may be missed by approaches focused on individual mutations.

Its primary screening product, FirstLook Lung, is a laboratory-developed blood test for adults eligible for lung cancer screening under USPSTF guidelines. The test helps assess the likelihood of detecting lung cancer through low-dose CT (LDCT), supporting decisions about referral for imaging. Designed for use through select health systems and healthcare providers, it includes provider support, electronic health record integration, and established clinical workflows. DELFI reports a 99.8% negative predictive value for a Not Elevated result.

DELFI also offers DELFI-TF for treatment monitoring and provides research services and partnerships for pharmaceutical organizations, including biomarker discovery and drug development. The company conducts clinical studies, including CASCADE-LUNG, to evaluate its screening approach in real-world patients.